Related Experiment Video

Updated: Aug 29, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia

L H Krut, H C Seftel, B I Joffe

    South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
    |March 12, 1977
    PubMed

    Insights

    Clofibrate and halofenate showed modest triglyceride and urate reductions in maturity-onset diabetics with hyperlipidaemia. Neither drug is recommended due to limited efficacy and adverse reactions.

    Area of Science:

    • Endocrinology
    • Metabolic Diseases
    • Pharmacology

    Background:

    • Hyperlipidaemia is a common comorbidity in maturity-onset diabetes.
    • Effective management of dyslipidemia in diabetic patients is crucial for preventing cardiovascular complications.

    Purpose of the Study:

    • To compare the efficacy and safety of clofibrate and halofenate in treating hyperlipidaemia in maturity-onset diabetics.
    • To evaluate the effects of these agents on serum lipids, urate levels, and glycemic control.

    Main Methods:

    • A 48-week, double-blind, randomized study.
    • Inclusion of maturity-onset diabetic patients with hyperlipidaemia.
    • Administration of clofibrate and halofenate, with assessment of clinical and biochemical parameters.

    Main Results:

    • Both drugs slightly lowered serum cholesterol and modestly, transiently reduced triglyceride levels.
    • Both significantly reduced serum urate, with halofenate showing a greater effect.
    • Halofenate demonstrated a notable hypoglycaemic effect, unlike clofibrate.
    • Adverse reactions led to premature discontinuation in approximately 20% of patients.

    Conclusions:

    • Neither clofibrate nor halofenate demonstrated sufficient efficacy or safety for managing hyperlipidaemia in maturity-onset diabetics.
    • The observed adverse effects and limited lipid-lowering capacity do not support their use in this patient population.

    More Related Videos

    Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment07:12

    Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

    Published on: June 2, 2023

    Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening06:50

    Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

    Published on: September 5, 2025

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

    Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

    Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
    Oral Hypoglycemic Agents: Sulfonylureas01:17

    Oral Hypoglycemic Agents: Sulfonylureas

    Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are typically...